Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Depreciation (2016 - 2025)

Ocular Therapeutix has reported Accumulated Depreciation over the past 13 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 16.45% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, up 16.45%, while the annual FY2025 figure was $27.5 million, 16.45% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $27.5 million at Ocular Therapeutix, up from $23.6 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $27.5 million in Q4 2025 and troughed at $15.2 million in Q4 2021.
  • A 5-year average of $20.8 million and a median of $20.3 million in 2023 define the central range for Accumulated Depreciation.
  • Biggest five-year swings in Accumulated Depreciation: grew 18.93% in 2021 and later rose 13.62% in 2022.
  • Year by year, Accumulated Depreciation stood at $15.2 million in 2021, then increased by 13.62% to $17.3 million in 2022, then increased by 17.26% to $20.3 million in 2023, then increased by 16.64% to $23.6 million in 2024, then increased by 16.45% to $27.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation for OCUL at $27.5 million in Q4 2025, $23.6 million in Q4 2024, and $20.3 million in Q4 2023.